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tified between January 1, 2007 and December 31, 2009. The surgical approach was
laparoscopic in 57.3%patients, and open in 42.7%patients.Mean cost per discharge
was significantly higher in open thoracic procedures compared to laparoscopic
procedures, $24,995 vs. $19,238, respectively(p0.001). Patients undergoing laparo-
scopic thoracic procedures had a significantly lower rate of surgical site infections
compared to patientswho underwent open procedures (4.8% vs. 5.8%, respectively,
p0.001). There was a significantly higher rate of blood transfusions with patients
undergoing open surgery compared to patients undergoing laparoscopic proce-
dures (13.2% vs. 6.3%, respectively, p0.001). CONCLUSIONS: Laparoscopic tho-
racic procedureswere associatedwith shorter hospital lengths of stay, lower rate of
surgical site infections, hemorrhage, blood transfusion and mortality rates. The
mean costs for laparoscopic procedures were significantly lower than mean costs
for open procedures. These observations highlight the potential cost advantages of
providing thoracic procedures through laparoscopic techniques as a method to
potentially save increasingly scarce healthcare funds for hospitals.
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OBJECTIVES: Analyze the differential in selected direct costs of a collaborative
structured blood glucose testing intervention in non-insulin treated patients with
type 2 diabetes mellitus (T2DM) when compared to enhanced usual care (active
control group (ACG)). METHODS: Data was derived from the Structured Testing
Program (STeP) - a 1 year, prospective, cluster-randomized, multicenter study that
examined the utility of a collaborative intervention using structured self-monitor-
ing of blood glucose (SMBG) in 483 poorly-controlled (HbA1c 7.5%) T2DM subjects
compared to the ACG. The structured testing group (STG) used the ACCU-CHEK®
360¢a View 3-day profile tool that facilitates collection and interpretation of 7-point
glucose profiles. From a US payer perspective, direct costs of diabetesmedications,
lab HbA1c tests, physician visits, and blood glucose testing strips associated with
STG were compared with ACG using student t-test at a significance level of 5%.
RESULTS: In the intent-to-treat population, STG showed a significantly greater
HbA1c reduction over 12 months than the ACG (-1.2% vs. 0.9%; 	-0.3%; p0.04).
During the study, STG incurred $180.95 mean PPPY (Pay per Patient Year) total
cost for diabetes medications, but -$173.73 mean PPPY for SMBG test strips, -$5.20
mean PPPY for labHbA1c tests, and -$2.15mean PPPY for physician visits compared
to ACG. There was no significant difference in direct costs between STG and ACG
(p 0.9898). CONCLUSIONS: Use of a collaborative structured testing intervention
improved HbA1c in STG without increasing direct cost. The increased STG medi-
cation cost was offset by a decreased use of blood glucose test strips. As previously
reported, STG subjects performed significantly fewer tests/day than ACG subjects
(mean  0.9 vs. 1.2, p0.0003) over the year. Structured testing, from a 1 year US
payer perspective, is an effective and overall cost-neutral tool for management of
non-insulin treated patients with type 2 diabetes.
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OBJECTIVES: Sensor-augmented pump therapy (SAPT) demonstrated a significant
reduction in HbA1c levels in type 1 diabetes patients compared to multiple daily
injections of insulin (MDI) in a recent randomized trial. We analyzed the data on
medical resource use collected within the trial and evaluated the long-term cost-
effectiveness of SAPT versusMDI in adultswith type 1 diabetes from the healthcare
systemperspective.METHODS:Wecombined estimates derived from the trial data
and the medical literature to populate the previously-validated CORE Diabetes
Model, which includes a series of Markov constructs that simulate the progression
of diabetes-related complications. During the 52-week trial period, SAPT patients
were provided insulin pumps and 3-day sensors. Electronic records indicated that
sensors were worn only by patients 65% of the time. The incremental reduction in
mean glycated hemoglobin was 0.6 percentage points in patients randomized to
SAPT relative to MDI. RESULTS: Among the 329 adults (19-70 years), mean age was
41 years andmeanduration of diabeteswas 20 years. Total treatment costs over the
52-week follow-up period were estimated at $10,760 for SAPT patients and $5,072
for MDI patients (2010 US$). Discounted (3% per year) lifetime estimates of direct
medical costs and QALYs were $253,493 and 10.794 for SAPT patients and $167,170
and 10.418 for MDI patients. The corresponding ICER was $229,675 per QALY (95%
CI: 139,071 to 720,865). Sensitivity analyses revealed that evolving technologies
could improve the cost-effectiveness of SAPT. With a 6-day sensor, the ICER de-
creased to $168,104 per QALY. Upon development of a 6-day sensor that requires
only one test strip per replacement for calibration, the ICER would drop to
$72,417/QALY. CONCLUSIONS: Our base-case findings revealed that the current
SAPT technology is not economically attractive. However, with technological ad-
vances currently in process, the cost-effectiveness of the SAPT could significantly
improve.
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OBJECTIVES: To assess the cost-effectiveness of epidermal growth factor receptor
(EGFR) gene mutation testing for guiding the application of gefitinib as first-line
therapy in patients with advanced non-small cell lung cancer (NSCLC) living in
Ontario. METHODS: A decision analytic model was developed to compare EGFR
gene mutation testing strategy versus no testing strategy in patients with ad-
vanced NSCLC. Under the testing strategy, patients tested positive for mutation
would receive gefitinib as first-line therapy. Under no testing strategy, patients
would receive conventional chemotherapy as first-line therapy. Probability vari-
ables were estimated through literature review. Utility variables were estimated
from a multivariate linear regression analysis taking into account of the clinical
responses and side-effects associated with treatment for NSCLC. Cost variables
were based on two Ontario cost studies for NSCLC. Both benefits and costs were
discounted at 5% per annum. RESULTS: Compared to no testing strategy, the in-
cremental cost-effectiveness ratio for EGFR gene mutation testing was $46,021 per
life year or $81,071 per quality adjusted life year (QALY). The cost-effectiveness of
EGFR gene mutation testing was sensitive to the cost and efficacy of gefitinib. The
budget impact analysis projected that EGFR gene mutation testing would cost On-
tario health care system $4.6M, $7.0M, $7.9M, $8.1M, and $8.1M more a year in the
next five years. CONCLUSIONS: EGFR gene mutation testing would not be cost-
effective in patients with advanced NSCLC in Ontario until willingness-to-pay was
above $81,000 per QALY. The efficacy and cost of gefitinib significantly affected the
cost-effectiveness of EGFR gene mutation testing.
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OBJECTIVES: A new prostate cancer detection index was developed as a combina-
tion of serum prostate-specific antigen (PSA), free PSA, and a PSA precursor form
[-2]proPSA to calculate the probability of prostate cancer and used as a diagnostic
aid for men age 50 years or older with PSA 4-10 ng/mL and nonsuspicious digital
rectal exam. The index has demonstrated improved specificity for detecting pros-
tate cancer over PSA test alone in clinical trials. The current study evaluated the
cost-effectiveness of early prostate cancer detection with the index adding to PSA
compared with PSA test alone from the U.S. societal perspective. METHODS: A
Markov model with probabilistic sensitivity analysis was constructed to estimate
the costs and health state utilities of prostate cancer detection and consequent
treatment for the annual prostate cancer screening of themale fromage 50 through
75 years. The transition probabilities, health state utilities, and prostate cancer
treatment costs were derived from the published literature. The diagnostic perfor-
mance of the index was obtained from a multi-center simulation study of the
index. Diagnostic related costs were obtained from the 2009 Medicare Fee Sched-
ule. Expected costs and effects were discounted at 3%. RESULTS: Over 25 annual
screening cycles, the strategy of the index adding to PSA dominated the PSA test
alone for prostate cancer detection. It was estimated to save $234, with an expected
gain of 0.02 quality adjusted life years (QALYs). The probability of the index test
being cost-effective is approximately 85% at the range of $50,000/QALY to $200,000/
QALY willingness to pay. Model results are most influenced by screening starting
age, discount rate, and biopsy utilization rates. CONCLUSIONS: The index as an aid
adding to PSA test may be an important strategy for prostate cancer detection as
compared to using PSA alone testing.
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OBJECTIVES: To assess the cost-effectiveness of CyberKnife (CK) compared to sur-
gery and radiation therapies for the treatment of localized prostate cancer (PC)
from societal and third party payer perspectives.METHODS: A Markov model was
used to compare treatmentwith CK, intensitymodulated radiation therapy (IMRT),
proton therapy (PT), and surgery, in 60-year-old patients. Themodel reflected both
procedure-relatedmortality and the comparative risks of long-term toxicity among
survivors, defined as adverse events grade 2 on Radiation Therapy Oncology
Group scale occurring at least 12 months following treatment: genitourinary (GU);
gastrointestinal (GI); and/or sexual dysfunction (SD). In the absence of evidence on
comparative effectiveness we assumed that long-term disease control andmortal-
ity would not differ across treatments. Toxicity probabilities were derived using
meta-analytical techniques. Utilities for adverse events were derived from a pub-
lished survey of PC patients using standard gamble technique. Model-projected
expected lifetime costs and quality adjusted life years (QALYs) for each treatment
were used to calculate the incremental cost-effectiveness of CK versus compara-
tors. The societal perspective included productivity costs owing to time spent in
treatment. Extensive sensitivity analyses were conducted. RESULTS: From a pay-
er’s perspective, surgery was least expensive followed by CK, IMRT and PT. How-
ever, CK patients had higher expected QALYs (9.54) than other options (9.08-9.49).
Incremental cost per QALY gained for CK versus surgery was $13,100/QALY. Com-
pared to IMRT and PT, CK was less costly with higher QALYs (dominant). From a
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societal perspective, CK costs $8,400/ QALY compared to surgery; CK remained
dominant versus IMRT and PT. Results were most sensitive to cost of CK and
surgery, and utility weights for GU and SD. CONCLUSIONS: CyberKnife was found
to be cost-effective versus surgery, and resulted in cost savings and improved
quality-adjusted survival compared to radiation options for the treatment of local-
ized PC.
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OBJECTIVES: Each year in Brazil, 42.3% of all inpatients present skin ulcers during
the hospitalization period. Current clinical practice guidelines have not established
a gold standard protocol of care for pressure ulcers. Thus, this study aimed to
develop cost-effectiveness analysis comparing three different dressings: hydrocol-
loid, silver sulfadiazine 1% cream (SSD) and saline gauze (SG), under the perspec-
tive of Brazilian public hospitals. METHODS: The mean time to healing (MTH) for
each protocol was obtained from systematic reviews. Data from the Brazilian Hos-
pital Information System from January 1st to December 31st 2009 was used to
define the annual number of hospital admissions due to pressure ulcers (only
non-surgical records with L89 ICD-10 code were included). The model assumed
that SG is the current practice in Brazilian public hospitals and patients are dis-
charged at the time their wound heals. The difference in MHT was applied to the
average length of stay (LOS) reported in the database. Resource use was estimated
through expert panel andunit costswere obtained fromBrazilian official price lists.
RESULTS: 934 hospitalizations were identified with mean LOS of 13.72 days. Hy-
drocolloid and SSD would reduce the MHT in 4.72 and 2.72 days, thus reducing
patients’ LOS. The cost per change was estimated as 15.52BRL, 43.20BRL and
15.72BRL and the cost per protocol per patient (daily room charges and dressing
changes) was 902.50BRL, 559.61BRL and 907.99BRL, for SG, hydrocolloid and SSD,
respectively. Adopting hydrocolloid as wound management protocol would save
342.89BRL per patient and -BRL320,259 for the 2009 cohort. SSD projected savings
was 5.49BRL per patient and -BRL5,125.79 for the entire cohort. CONCLUSIONS:
Hydrocolloid dressing has shown higher efficacy when compared to SG or SSD
dressings, with fewer costs. The clinical and economic incremental results be-
tween different dressings reinforce the need of evidence-based decision making
and rational resource allocation.
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OBJECTIVES: Congenital hypothyroidism (CH) is a serious conditions and expen-
sive illness. The purpose of this study was to develop an economic model in order
to evaluate the cost-effectiveness ratios between two heel lancet devices in terms
success of the procedure in neonates undergoing the newborn screening test at the
Social Security Mexican Institute (IMSS) from the health care payer’s perspective.
METHODS: A cost-effectiveness analysis was developed using a decision-tree
model. Themodel simulates costs and effectiveness outcomes in a 15 years period.
The comparators were: Heel lance BD Safety-Flow lancet® and the BD QuikHeel
lancet®. The effectiveness measure was the number of cases of severe congenital
hypothyroidism avoided at the end of the follow-up period. Effectiveness data and
transition probabilities were taken from international published literature. The
estimation of resource use was performed employing local expert opinion surveys.
Cost and effectiveness were discounted 5% annually. The model was calibrated
according to international pharmacoeconomics guidelines. One-way and probabi-
listic sensitivity analyses were performed using Monte Carlo Simulation second-
order approach. RESULTS: Regarding effectiveness, the lancet Contact Activated
would prevent 75% of patients with CH detected in advanced stages and with the
use of the lancet Quickheel the percentage would increase to 98%, preventing 23%
more cases of severe CH. Themean cost per newborn screened in case of using the
lancet type would Contact Activated $12.2 and with the lancet Quikheel type
$11.71. The potential savings from the use of the lancet Quikheel would be around
$779,545.75 in the hold program. CONCLUSIONS:With these data we can conclude
that the use of the lancet Quikheel type is the best alternative, as it offers better
results at lower cost. In Mexico the use of the lancet Quikheel brings significant
clinical and economic benefits that make of the neonatal screening program a
better one.
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OBJECTIVES:Diabetes is a growing cause of death andmorbidity inmiddle-income
countries carrying a large financial burden for health systems. In recent years,
diabetes screening practices in Colombia have shifted from using the fasting glu-
cose test (FGT) towards relying on glycosylated hemoglobin (HbA1c) as physicians
consider it a more reliable tool to early detect diabetes. This analysis assesses the
cost-effectiveness of alternative screening strategies in general population in Co-
lombia from a health system perspective. METHODS: A decision-analytic model
was designed to compare four strategies: (1) FGT  confirmatory FGT (standard
practice); (2) FGT confirmatory HbA1c; (3) Only HbA1c and (4) no screening. Long-
term health outcomes (life years) and cost-outcomes were modeled via a 20-year
Markov model with three diabetes states: non-complicated, complicated diabetes
and death. Parameter values were based on data from the National Health Survey
and from the Ministry of Social Protection on general population. The model pro-
jectionswere comparable to those published elsewhere using CORE andColombian
literature on diabetes costs. One-way sensitivity analysis on the HbA1c cost was
also performed. RESULTS: No significant differences on costs per life-year saved
were found when comparing FGT  confirmatory FGT ($1,047) and FGT  confir-
matory HbA1c ($1,069) against no-screening. However, the use of only HbA1c was
associated with a higher cost per life-year saved ($2,455.93) when comparing
against no-screening. This result was mainly driven by not using a confirmatory
test rather than by the test itself. CONCLUSIONS: This analysis found the perfor-
mance of FGT confirmatory FGT and FGT confirmatory HbA1c to be similar and
highly cost-effective in general population older than 45when in comparison to no
screening. This finding has implications in both clinical and healthcare policymak-
ers in Colombia and in other Latin American countries with similar diabetes prev-
alence and treatment options.
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OBJECTIVES: The primary analysis of this study was to estimate the cost-effective-
ness of TAVI compared to standard management (SM) in inoperable patients with
severe, symptomatic aortic valve stenosis (SSAVS). The secondary analysis was to
preliminarily explore both the cost-effectiveness and value of information of TAVI
compared to surgical aortic valve replacement (SAVR) in operable patients at high
surgical risk with SSAVS.METHODS: A combined decision tree and Markov model
was developed to compare the costs, life-years (LYs) and quality-adjusted life-
years (QALYs) of TAVI (transfemoral (TF) and transapical (TA) approaches) to SM
and SAVR over a 5-year time horizon. This evaluation was conducted from a third
party payer’s perspective. RESULTS: In the primary analysis, comparing TF and SM
resulted in an incremental cost-effectiveness ratio (ICER) of $126,874/LY and
$222,378/QALY. Comparing TA and SM resulted in an ICER of $262,672/LY and
$1,454,241/QALY. In the secondary analysis, TF and SAVRwere compared, resulting
in an ICER of $39,676/LY and $81,758/QALY. Comparing TA and SAVR resulted in an
ICER of $183,454/LY. TAwas dominated by SAVRwhen comparing QALYs. The total
expected value of perfect information (EVPI) was at a maximum with a value of
$6,928 at a WTP threshold of $80,000/QALY. The expected value of partial perfect
information (EVPPI) was highest for the 30-day clinical event rates when compared
to the EVPPI values for the 1-year, 2-year and 3-year clinical event rates.
CONCLUSIONS: This economic evaluation suggested that TAVI might not be a
cost-effective option for inoperable patients in comparison to SM. The secondary
analysis suggested that TAVI might be a cost effective option for operable patients
compared to SAVR. To reduce the uncertainty in our estimate it might be worth-
while to obtain empirical evidence related to clinical event rates occurring 30-days
post operation.
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OBJECTIVES:New technologies in screening and treatment of diabetic retinopathy
(DR) and diabetic macular edema (DME) have emerged recently. The goal of this
systemic literature review is to identify and compare critical gaps in the published
economic evaluation literatures for screenings and treatments strategies of
DR/DME. METHODS: A systematic literature search was conducted to identify lit-
erature in English from 1980-2010, using PubMed, Embase, NHS NICE EED, and Tuft
CEA Registry. Key terms included “diabetic retinopathy”, “diabetic macular
edema”, and relevant terms for economic evaluations. All studies related to eco-
nomic analysis and decisionmodeling were included. Studies that focused only on
cost or utility were excluded. RESULTS: 52 articles were identified and 33 were
excluded based on the pre-specified exclusion criteria. Of the remaining 19 studies,
nine (47%) focused on screening methods, six (32%)on diabetic care, and four (21%)
on DR/DME treatment. Among the included studies, 12 studies (63%) were cost-
effective analyses, and sight-years saved was the most frequently used endpoint.
Seven studies (37%) were cost-utility analyses. A broad range of decision-analytic
frameworks and health state descriptions were observed. Some only assigned util-
ity to blindness, not to diabetic patients whomay have impaired quality of life due
to vision loss. In addition, although DR/DME is a bilateral condition, most studies
did not clearly explain how cost, utility, and disease progression were modeled for
the second eye.CONCLUSIONS:This literature review identified a range of decision
analytic frameworks, health states definitions, and utility sources employed in
economic evaluations of screening and treatment of DR/DME. Future studies as-
sessing cost-effectiveness of new technologies should transparently address these
areas.
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